CHPA testifies during FDA meeting for Sanofi switch application

Senior Vice President, Policy, and General Counsel & Secretary David Spangler underscores value of Rx-to-OTC switches to U.S. healthcare system

Washington, D.C. (July 31, 2013)—The Consumer Healthcare Products Association (CHPA) spoke today during a Food and Drug Administration (FDA) Advisory Committee meeting, during which the committee discussed the data submitted by Sanofi to support an application to switch triamcinolone acetonide nasal spray from prescription to over-the-counter (OTC) status. CHPA Senior Vice President, Policy, and General Counsel & Secretary David Spangler spoke on behalf of CHPA, highlighting how the power of access through prescription-to-OTC switch benefits consumers and the healthcare system.

CHPA applauds the advisory committee for voting that the benefit/risk profile of Nasacort AQ Nasal Spray is appropriate for OTC use. If approved by FDA, this would be the second first in class switch in the last 12 months.

Spangler’s presentation is available online.

Contact: Jenni Terry, 202.429.0469


CHPA is the 132-year-old trade association representing U.S. manufacturers and distributors of over-the-counter medicines and dietary supplements.